Investors

Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives.  Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases.

Recent Updates

Stock DetailsStock Summary | |
Volume:
Updated

IR Contacts

Primary IR Contact

Stacey L. Jurchison
Senior Director, Investor Relations & Corporate Communications
Phone: 206.859.6628
E-mail: jurchisons@apvo.com